Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis"

Affiliations

• ¹ Gastrounit, Medical Division, Copenhagen University Hospital, Hvidovre, Denmark; Copenhagen Center for Inflammatory Bowel Disease in Children, adolescents and adults, University of Copenhagen, Hvidovre Hospital, Denmark; Department of Gastroenterology and Hepatology, Herlev Hospital, University of Copenhagen, Denmark. Electronic address: Mohamed.Attauabi.01@regionh.dk.
• ² Department of Gastroenterology and Hepatology, Herlev Hospital, University of Copenhagen, Denmark.
• ³ Gastrounit, Medical Division, Copenhagen University Hospital, Hvidovre, Denmark; Copenhagen Center for Inflammatory Bowel Disease in Children, adolescents and adults, University of Copenhagen, Hvidovre Hospital, Denmark.